Navigation Links
Announcement - Clontech Laboratories, Inc. Releases the iDimerize™ Cell Signaling and Expression Systems
Date:4/20/2011

MOUNTAIN VIEW, Calif., April 20, 2011 /PRNewswire/ -- Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the release of the iDimerize inducible dimerization systems. Based on the widely used ARGENT™ technology developed by ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA), the iDimerize systems enable precise, real-time control of protein-protein interactions using specific cell-permeable chemical ligands, called dimerizers. Any cellular process that can be activated or inactivated by protein-protein interactions can be controlled in real time by dimerizers, either in vitro or in vivo, by fusing the proteins of interest to specific dimerization domains.

Carol Lou, General Manager of Clontech Laboratories, Inc., comments: "Clontech has a long history of leadership in the development of technologies for understanding gene function. We are pleased to collaborate with ARIAD to add the proven and established iDimerize inducible dimerization systems to our portfolio of protein expression and function control systems, which include the Tet-On® 3G and Tet-Express™ systems for inducible gene expression and the ProteoTuner™ systems for inducible protein stabilization."  

The iDimerize systems are based, in part, on technology and intellectual property initially developed by faculty at Harvard and Stanford Universities and further developed and optimized by ARIAD scientists to create the ARGENT technology. Inducible dimerization is a powerful tool to validate the specific role of a prot
'/>"/>

SOURCE Clontech Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cepheid Schedules 2010 Third Quarter Financial Results Announcement and Webcast
2. Announcement of 2010 Kavli Prize laureates
3. Update: Event advisory -- announcement of 2010 Kavli Prize laureates
4. Astrogenetix Statement On Nasa's Fiscal Year 2011 Budget Announcement
5. Datafarm Responds to Health Canada's Announcement of Hybrid eCTD Submission Procedural Simplification
6. Cepheid Schedules 2009 Third Quarter Financial Results Announcement and Webcast
7. Nobelprize.org Expands Channels and News Services for the 2009 Nobel Prize Announcements
8. Warsaw, Ind. Orthopedics Industry and Community Leaders to Make Major Announcement
9. Nektar Therapeutics to Host Conference Call to Discuss Todays Announcement of a New Partnership for NKTR-118 and NKTR-119
10. Cepheid Schedules 2009 Second Quarter Financial Results Announcement and Webcast
11. Inverness Medical Innovations - Concateno plc, Further Announcement Regarding UK Takeover Code Share Dealing Disclosure Requirements.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Ceres, Inc . (Nasdaq: CERE ), an ... for the three months ended May 31, 2014 and ... reported that the company and its customers have made ... Brazil, which concluded in June, despite dry and hot ... part of the growing season. Yields of several of ...
(Date:7/10/2014)... today in the journal PNAS (Proceedings of the ... of day and sleep deprivation have a significant effect ... looking at the best time of day to test ... for administering medicines effectively. , Researchers from the University ... investigated the links between sleep deprivation, body clock disruption ...
(Date:7/10/2014)... geckos and spiders can sit upside down forever. Nanophysics makes ... this in an article just published in Physical Review ... , Geckos and spiders that seem to be able to ... researchers worldwide for many years. We will soon be able ... as the gecko,s foot. But the fact is, sooner or ...
(Date:1/15/2014)... assembling a club sandwich at the nanoscale, National ... succeeded in crafting a uniform, multi-walled carbon-nanotube-based coating ... used in upholstered furniture and other soft furnishings. ... was reduced 35 percent compared with untreated foam. ...
Breaking Biology Technology:Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Time of day crucial to accurately test for diseases, new research finds 2Even geckos can lose their grip 2Layered security: Carbon nanotubes promise improved flame-resistant coating 2
... allows up to 50% sucrose reduction while maintaining the sweet taste ... ... CA, July 29, 2008 Senomyx, Inc.,(Nasdaq: SNMX ), a ... flavor ingredients for the food, beverage,and ingredient supply industries, announced today ...
... technology to an,orphan disease, in a unique translational ... July 29 ,ALS Therapy Development Institute (ALS TDI) ... new collaboration aimed at advancing any potential,application of ... sclerosis,commonly known as Lou Gehrig,s diseases. The new ...
... Zenobia Therapeutics, Inc.,(Zenobia) announced today that ... from The Michael J. Fox Foundation for ... potential to,fundamentally alter the course of Parkinson,s ... Ross of Johns Hopkins University,Zenobia will discover ...
Cached Biology Technology:SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW SUCROSE ENHANCER 2SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW SUCROSE ENHANCER 3SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW SUCROSE ENHANCER 4ALS Therapy Development Institute and California Stem Cell, Inc. Announce Long-Term Scientific Collaboration 2ALS Therapy Development Institute and California Stem Cell, Inc. Announce Long-Term Scientific Collaboration 3Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinson's Research Award for Work on PD-implicated Protein LRRK2 2
(Date:7/10/2014)... JUPITER, FL, July 10, 2014 Amidst the astounding ... of synaptic connections in the brain, how do nerve ... connections to build? How do they coordinate these events ... scientists from the Florida campus of The Scripps Research ... processes, showing that a particular protein plays a far ...
(Date:7/10/2014)... Amyloid diseases, such as Alzheimer,s disease, type 2 ... the common trait that proteins aggregate into long ... studies have found that neither the amylin monomer ... New evidence using two-dimensional infrared (2D IR) spectroscopy ... aggregation pathway that may explain toxicity, opening a ...
(Date:7/10/2014)... Ore. Nuclear engineers at Oregon State University have ... device that should help people all over the world ... intensity, and whether or not it poses a health ... to public demand following the nuclear incident in Fukushima, ... what level of radiation they were being exposed to ...
Breaking Biology News(10 mins):Scripps Florida scientists shed new light on nerve cell growth 2New technology reveals insights into mechanisms underlying amyloid diseases 2Sophisticated radiation detector designed for broad public use 2Sophisticated radiation detector designed for broad public use 3
... Lee Lovering, Ph.D., School of Biosciences, University of ... Award for his seminal work on the structural ... and modify cell walls in bacteria. Natalie Strynadka, ... Lovering,s work: "his spectacular abilities in structural biology ...
... 2012) Aeras and the Infectious Disease Research Institute ... trial of IDRI,s novel tuberculosis vaccine candidate, ID93 + ... safety, tolerability and immunogenicity of the vaccine candidate in ... by Johnson County Clin-Trials in Lenexa, Kansas, in close ...
... risks posed to people who work with tiny fibres used ... Research into the health risks posed by nanofibres ... has pinpointed the lengths at which these fibres are ... from a range of materials including carbon, are about 1,000 ...
Cached Biology News:The American Society for Microbiology honors Andrew Lovering 2As TB grows more difficult to control, vaccine candidate to prevent disease enters clinical testing 2